LUCA launched to make 'true impact' with vaginal microbiome research

6 August 2019

The first biotech to emerge from the foundry model of Seed Health is building on 15 years of research by Jacques Ravel, a leading scientist in the vaginal microbiome division of the National Institutes of Health Human Microbiome Project.

LUCA Biologics will develop live biotherapeutics for widespread, unmet medical needs in women's health, with Dr Ravel serving as chief scientist.

The company’s first therapeutic targets urinary tract infection (UTI), estimated by the World Health Organization to impact half of women globally, and the most common bacterial infection in the USA.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK